• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Monday

    7/31/23 2:54:35 PM ET
    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVC alert in real time by email

     

    On Monday, 27 stocks hit new 52-week lows.

    Interesting Points From Today's 52-Week Lows:

    • The largest company by market cap to hit a new 52-week low was Apellis Pharmaceuticals (NASDAQ:APLS).
    • Esports Entertainment (NASDAQ:GMBL) was the smallest company by market cap to set a new 52-week low.
    • Theratechnologies (NASDAQ:THTX)'s stock came under the most pressure, trading down 252.48% to reach a new 52-week low.
    • Artesian Resources (NASDAQ:ARTNA) shares bounced back the most, actually rising 0.04% after hiting a new 52-week low.

    The following stocks set new 52-week lows on Monday:

    • Apellis Pharmaceuticals (NASDAQ:APLS) shares moved down 18.14% on Monday to hit a new 52-week low of $25.48, drifting down 18.14%.
    • Impinj (NASDAQ:PI) shares hit a yearly low of $65.03. The stock was down 2.54% on the session.
    • Artesian Resources (NASDAQ:ARTNA) shares made a new 52-week low of $45.27 on Monday. The stock was down 0.04% for the day.
    • Vanda Pharma (NASDAQ:VNDA) shares hit a yearly low of $5.58. The stock was down 2.61% on the session.
    • Prelude Therapeutics (NASDAQ:PRLD) stock dropped to a yearly low on Monday of $3.92. Shares traded down 1.51%.
    • SWK Holdings (NASDAQ:SWKH) stock hit a yearly low of $15.87. The stock was up 0.38% for the day.
    • Silicom (NASDAQ:SILC) stock hit a yearly low of $29.00. The stock was down 25.43% for the day.
    • Complete Solaria (NASDAQ:CSLR) shares set a new 52-week low of $3.31. The stock traded down 7.95%.
    • Matinas BioPharma Hldgs (AMEX:MTNB) stock hit a new 52-week low of $0.32. The stock was down 8.33% on the session.
    • CEL-SCI (AMEX:CVM) shares set a new 52-week low of $1.51. The stock traded down 6.12%.
    • Dare Bioscience (NASDAQ:DARE) shares reached a new 52-week low of $0.73 on Monday morning, moving up 0.47%.
    • Delta Apparel (AMEX:DLA) shares set a new 52-week low of $8.36. The stock traded down 3.24%.
    • Theratechnologies (NASDAQ:THTX) shares set a new 52-week low of $1.74. The stock traded up 252.48%.
    • Purple Biotech (NASDAQ:PPBT) shares fell to $1.02 on Monday, setting a new 52-week low with a shift of down 4.5%.
    • Datasea (NASDAQ:DTSS) stock set a new 52-week low of $0.71 on Monday, moving down 3.97%.
    • Capstone Green Energy (NASDAQ:CGRN) shares set a new 52-week low of $0.92. The stock traded down 4.9%.
    • GRI Bio (NASDAQ:GRI) shares made a new 52-week low of $3.45 on Monday. The stock was up 2.59% for the day.
    • Pop Culture Gr (NASDAQ:CPOP) stock hit a new 52-week low of $0.39. The stock was down 3.15% on the session.
    • ABVC BioPharma (NASDAQ:ABVC) shares reached a new 52-week low of $2.46 on Monday morning, moving down 5.58%.
    • Biolase (NASDAQ:BIOL) shares hit a yearly low of $5.75. The stock was down 10.07% on the session.
    • Takung Art (AMEX:TKAT) stock achieved a new 52-week low on Monday morning, hitting $0.16 and moving down 14.68%.
    • Bone Biologics (NASDAQ:BBLG) stock set a new 52-week low of $1.24 on Monday, moving down 2.27%.
    • Eightco Holdings (NASDAQ:OCTO) shares made a new 52-week low of $1.30 on Monday. The stock was down 4.14% for the day.
    • Blue Star Foods (NASDAQ:BSFC) stock hit a yearly low of $0.85. The stock was down 13.73% for the day.
    • Esports Entertainment (NASDAQ:GMBL) shares set a new yearly low of $0.40 this morning. The stock was down 6.98% on the session.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ABVC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $APLS
    $ARTNA
    $BBLG

    CompanyDatePrice TargetRatingAnalyst
    Impinj Inc.
    $PI
    11/7/2025$200.00Neutral
    UBS
    Apellis Pharmaceuticals Inc.
    $APLS
    11/6/2025Peer Perform
    Wolfe Research
    Vanda Pharmaceuticals Inc.
    $VNDA
    11/5/2025$11.00Buy
    B. Riley Securities
    Apellis Pharmaceuticals Inc.
    $APLS
    10/15/2025$32.00Overweight
    Wells Fargo
    Impinj Inc.
    $PI
    10/8/2025$200.00Overweight
    Barclays
    Apellis Pharmaceuticals Inc.
    $APLS
    9/26/2025$18.00Neutral → Sell
    Goldman
    Apellis Pharmaceuticals Inc.
    $APLS
    5/9/2025$23.00Buy → Neutral
    BofA Securities
    Apellis Pharmaceuticals Inc.
    $APLS
    5/9/2025$52.00Strong Buy → Outperform
    Raymond James
    More analyst ratings

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Washington Miron sold $54,357 worth of shares (342 units at $158.94), decreasing direct ownership by 14% to 2,040 units (SEC Form 4)

    4 - IMPINJ INC (0001114995) (Issuer)

    11/7/25 6:13:42 PM ET
    $PI
    Industrial Machinery/Components
    Technology

    SEC Form 4 filed by Director Sandor Victor

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    11/7/25 4:28:31 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    See Footnotes Sylebra Capital Llc sold $305,641 worth of shares (1,513 units at $202.01) (SEC Form 4)

    4 - IMPINJ INC (0001114995) (Issuer)

    11/5/25 8:24:59 PM ET
    $PI
    Industrial Machinery/Components
    Technology

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    SEC Filings

    View All

    SEC Form S-3 filed by Cel-Sci Corporation

    S-3 - CEL SCI CORP (0000725363) (Filer)

    11/7/25 4:31:11 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Prelude Therapeutics Incorporated

    SCHEDULE 13G - Prelude Therapeutics Inc (0001678660) (Subject)

    11/7/25 4:01:48 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Artesian Resources Corporation

    10-Q - ARTESIAN RESOURCES CORP (0000863110) (Filer)

    11/7/25 12:41:27 PM ET
    $ARTNA
    Water Supply
    Utilities

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS initiated coverage on Impinj with a new price target

    UBS initiated coverage of Impinj with a rating of Neutral and set a new price target of $200.00

    11/7/25 8:30:20 AM ET
    $PI
    Industrial Machinery/Components
    Technology

    Wolfe Research initiated coverage on Apellis Pharmaceuticals

    Wolfe Research initiated coverage of Apellis Pharmaceuticals with a rating of Peer Perform

    11/6/25 8:48:03 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Vanda Pharma with a new price target

    B. Riley Securities initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $11.00

    11/5/25 7:30:12 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO O'Donnell Kevin J bought $250,000 worth of shares (171,233 units at $1.46) and was granted 400,000 shares, increasing direct ownership by 1,987% to 599,985 units (SEC Form 4)

    4 - Eightco Holdings Inc. (0001892492) (Issuer)

    9/11/25 8:07:01 AM ET
    $OCTO

    Director Jennings Frank D bought $200,000 worth of shares (136,986 units at $1.46), increasing direct ownership by 796% to 154,189 units (SEC Form 4)

    4 - Eightco Holdings Inc. (0001892492) (Issuer)

    9/10/25 3:59:46 PM ET
    $OCTO

    Director Caiano Nicola Paul was granted 2,960 shares and bought $500,000 worth of shares (342,466 units at $1.46), increasing direct ownership by 7,105% to 350,288 units (SEC Form 4)

    4 - Eightco Holdings Inc. (0001892492) (Issuer)

    9/10/25 3:58:39 PM ET
    $OCTO

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

    SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 13, 2025, to review its financial results for the quarter ended September 30, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 5794075. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website a

    11/6/25 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference

    WASHINGTON, Nov. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Stifel 2025 Healthcare Conference in New York City on Wednesday, November 12, 2025. A corporate presentation is scheduled for 4:40 p.m. Eastern Time. The corporate presentation given at the Stifel conference may be accessed live on Vanda's corporate website, www.vandapharma.com. Investors should click on the Investors tab and follow the links under Recent Events. Investors are advised to go to the conference websites at least 15 mi

    11/5/25 5:00:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

    WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:40 p.m. ET. The live conference webcast will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the fir

    11/5/25 7:00:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Financials

    Live finance-specific insights

    View All

    Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

    SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 13, 2025, to review its financial results for the quarter ended September 30, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 5794075. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website a

    11/6/25 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Announces Strategic Business Update

    Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company's preliminary estimates, and potentially into the third quarter of 2028 if Incyte exercises option on JAK2 program Company to release third quarter 2025 financial results and conduct an investor conference call on November 12, 2025 WILMIN

    11/4/25 7:05:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artesian Resources Corporation Announces Second 2% Increase This Year in Quarterly Common Stock Dividend

    NEWARK, Del., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Artesian Resources Corporation (NASDAQ:ARTNA) announced today that its Board of Directors has approved a 2% increase in the quarterly common stock dividend, which will mark a 4% increase for the year. This increase will raise the quarterly dividend to $0.3136 per share on the company's Class A and Class B Common Stock payable November 24, 2025 to shareholders of record at the close of business on November 14, 2025, lifting the annualized dividend rate to $ 1.2544 per share. "Artesian continues to execute our strategic growth plan for wastewater and water services, expanding our customer base in a manner that strengthens operational efficienc

    10/30/25 3:10:00 PM ET
    $ARTNA
    Water Supply
    Utilities

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Leadership Updates

    Live Leadership Updates

    View All

    SunPower Executes Major Sales Force Expansion Following Sunder Merger

    OREM, Utah, Oct. 30, 2025 (GLOBE NEWSWIRE) -- SunPower Inc. (NASDAQ:SPWR) a solar technology, services, and installation company, this morning announced the successful integration of the Sunder salesforce into the company — as SunPower continues to execute on plan and expects to achieve record revenue of $83.3 million and record operating income of $3.5 million in Q4 2025. Eric Nielsen, SunPower's EVP of Sales said, "I am happy to report the integration of Sunder's salesforce into SunPower has been seamless and as a result, has enabled our team to continue to execute on plan without missing a beat. In addition, this deal has been well received across the industry — evidenced by the fact t

    10/30/25 8:00:00 AM ET
    $CSLR
    $SPWR
    Semiconductors
    Technology

    Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

    WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of Directors, effective today. Ms. Dorton has more than 30 years of industry expertise and leadership in healthcare and life sciences including service on several boards of public life science companies, executive financial leadership and investment banking. "Katina brings to Prelude an abundance of experience as a strategic and financial advisor to our leadership team," stated Kris Vaddi, Ph.D., Chief Executive Officer of Prelude. "We welcome her to our board and we look forward to

    10/17/25 7:30:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SPWR to Acquire Sunder Energy to Gain U.S. No. 5 Spot

    OREM, Utah, Sept. 22, 2025 (GLOBE NEWSWIRE) -- SunPower (formerly d/b/a Complete Solaria, Inc.; herein "SunPower," the "Company" or Nasdaq: "SPWR") – a solar technology, services, and installation company – today announced that it has agreed to acquire Sunder Energy, based in South Jordan, Utah, the No. 11 U.S. solar company by installed megawatts as reported by Ohm Analytics. The transaction is scheduled to close this week subject to customary closing conditions. Management will host a call today at 11am PT / 2pm ET to discuss the merger. Interested parties may access the webcast by registering via the link here or by visiting the Events page found within the IR section of the company web

    9/22/25 8:00:00 AM ET
    $CSLR
    $SPWR
    Semiconductors
    Technology

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

    SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 8:47:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Blue Star Foods Corp.

    SC 13G/A - Blue Star Foods Corp. (0001730773) (Subject)

    11/14/24 7:34:10 PM ET
    $BSFC